Novel targets for myeloma bone disease

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80% of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients.

Original languageEnglish (US)
Pages (from-to)1377-1387
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Bone Diseases
Multiple Myeloma
Bone
Bone and Bones
Clinical Trials
Bone Remodeling
Bone Development
Osteoclasts
Plasma Cells
Osteoblasts
Osteogenesis
Neoplasms
Bone Marrow
Tumors
Therapeutics
Pharmaceutical Preparations
Plasmas

Keywords

  • Bone disease
  • Myeloma
  • Novel treatments
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Novel targets for myeloma bone disease. / Roodman, G. David.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 11, 11.2008, p. 1377-1387.

Research output: Contribution to journalArticle

@article{c981ca848b8d436e8a6bc32f2b7f209d,
title = "Novel targets for myeloma bone disease",
abstract = "Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80{\%} of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients.",
keywords = "Bone disease, Myeloma, Novel treatments, Osteoblast, Osteoclast",
author = "Roodman, {G. David}",
year = "2008",
month = "11",
doi = "10.1517/14728222.12.11.1377",
language = "English (US)",
volume = "12",
pages = "1377--1387",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Novel targets for myeloma bone disease

AU - Roodman, G. David

PY - 2008/11

Y1 - 2008/11

N2 - Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80% of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients.

AB - Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80% of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients.

KW - Bone disease

KW - Myeloma

KW - Novel treatments

KW - Osteoblast

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=56249122936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249122936&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.11.1377

DO - 10.1517/14728222.12.11.1377

M3 - Article

C2 - 18851694

AN - SCOPUS:56249122936

VL - 12

SP - 1377

EP - 1387

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -